Barclays Boosts DaVita (NYSE:DVA) Price Target to $169.00

DaVita (NYSE:DVA) had its target price increased by analysts at Barclays from $164.00 to $169.00 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Barclays‘s target price indicates a potential upside of 7.68% from the company’s previous close.

DaVita Price Performance

DVA opened at $156.95 on Tuesday. The company has a debt-to-equity ratio of 15.78, a quick ratio of 1.33 and a current ratio of 1.37. DaVita has a 1-year low of $118.56 and a 1-year high of $179.60. The company has a 50-day moving average of $161.39 and a 200-day moving average of $157.80. The company has a market capitalization of $12.87 billion, a P/E ratio of 16.93, a PEG ratio of 0.84 and a beta of 0.94.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, beating the consensus estimate of $2.14 by $0.10. DaVita had a return on equity of 88.18% and a net margin of 6.53%. Equities analysts expect that DaVita will post 9.71 EPS for the current fiscal year.

Institutional Trading of DaVita

Institutional investors have recently added to or reduced their stakes in the business. Exchange Traded Concepts LLC acquired a new position in shares of DaVita in the 3rd quarter valued at about $135,000. Vontobel Holding Ltd. lifted its holdings in DaVita by 17.2% in the third quarter. Vontobel Holding Ltd. now owns 2,243 shares of the company’s stock worth $368,000 after acquiring an additional 329 shares during the last quarter. Capital Investment Advisors LLC acquired a new position in DaVita in the third quarter valued at approximately $213,000. Blue Trust Inc. grew its holdings in shares of DaVita by 56.4% during the third quarter. Blue Trust Inc. now owns 330 shares of the company’s stock valued at $54,000 after purchasing an additional 119 shares during the last quarter. Finally, Raymond James & Associates raised its position in shares of DaVita by 93.6% during the 3rd quarter. Raymond James & Associates now owns 31,316 shares of the company’s stock worth $5,134,000 after purchasing an additional 15,138 shares during the period. Institutional investors own 90.12% of the company’s stock.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.